Understanding the long-term effects of HIV medications on bone and fat health in children
Official title: Identifying the long-term metabolic complications of in-utero and lactational antiretroviral exposure
Funded at Rush University Medical Center · NIH-10762179 · Data updated 2026-11-12
This study is looking at how taking HIV medicine during pregnancy and breastfeeding might affect kids' bone and fat growth, so we can better understand the safety of these treatments for moms and their little ones.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rush University Medical Center NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | September 6, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $158,000 |
| NIH project number | 1R03HD113500-01 |
| Project ID | NIH-10762179 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include children who were exposed to dolutegravir-based ART in utero or during breastfeeding.
✕Less likely to help
Patients who were not exposed to antiretroviral therapy during pregnancy or lactation may not benefit from this research.
What this research studies
This research investigates the long-term metabolic effects of antiretroviral therapy (ART) exposure during pregnancy and breastfeeding on children. It focuses on understanding how exposure to dolutegravir-based ART affects bone and fat development in young individuals. By analyzing banked biological samples from a previous study, the researchers will employ advanced imaging and molecular techniques to assess changes in bone mass and quality, as well as fat tissue characteristics. This study aims to fill a critical knowledge gap regarding the safety of current HIV treatments for mothers and their children.
Why it matters
Potential benefit: If successful, this research could lead to improved guidelines for the use of HIV medications in pregnant women, ensuring better health outcomes for their children.
How similar studies have gone: While there is existing research on the effects of non-DTG based ART, this specific investigation into dolutegravir's long-term effects is novel and untested.
Where this research is happening
-
Rush University Medical Center
Chicago, United States Active
Researchers
- Principal investigator: Ross, Ryan Dee — Rush University Medical Center
- Study coordinator: Ross, Ryan Dee
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.